Cystatin C as an early marker of cardiovascular risk in patients with diabetes
DOI:
https://doi.org/10.56294/saludcyt2024684Keywords:
Cystatin C, Diabetes Mellitus, Biomarkers, Risk Factors, Early Diagnosis, Cardiovascular DiseasesAbstract
Introduction: cystatin C, a protein with stable plasma concentration and exclusive renal elimination, has been highlighted as a promising early marker of cardiovascular risk in diabetic patients due to its relationship with renal function and inflammation.
Objective: to identify in the existing literature the association between Cystatin C and cardiovascular risk in patients with diabetes, evaluating its potential as a marker by means of a systematic review.
Methods: we performed exhaustive searches of scientific databases and selected ten studies that met the inclusion criteria. These studies focused on the evaluation of Cystatin C expression profiles and their effectiveness as a marker in the diagnosis and prognosis of cardiovascular disease. The PRISMA method was used.
Results: the studies reveal that cystatin C is closely associated with type 2 diabetes, predicts cardiovascular disease, and provides an accurate assessment of renal function in diabetic patients, highlighting its usefulness as an early marker of complications. Furthermore, elevated cystatin C levels correlate with increased mortality and cardiovascular risk, surpassing in accuracy other traditional markers, positioning it as a key indicator in the comprehensive assessment of risk and prognosis in diabetic patients.
Conclusions: cystatin C shows promising links with diabetes and cardiovascular risk in diabetic patients, suggesting its usefulness as an early marker. Although it offers the potential for detecting renal and cardiac complications, further research is required before its widespread clinical implementation
References
1. OMS. Diabetes 2023. https://www.who.int/es/news-room/fact-sheets/detail/diabetes (accedido 3 de octubre de 2023).
2. Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019;26:25-32. https://doi.org/10.1177/2047487319878371.
3. Lees JS, Mark PB. Cystatin C to predict renal disease and cardiovascular risk. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 21;36:39-41. https://pubmed.ncbi.nlm.nih.gov/32514520/.
4. Pabich M, Materska M. Biological Effect of Soy Isoflavones in the Prevention of Civilization Diseases. Nutrients 2019;11:1660. https://doi.org/10.3390/nu11071660.
5. Sapkota S, Khatiwada S, Shrestha S, Baral N, Maskey R, Majhi S, et al. Diagnostic Accuracy of Serum Cystatin C for Early Recognition of Nephropathy in Type 2 Diabetes Mellitus. Int J Nephrol 2021;2021:1-7. https://doi.org/10.1155/2021/8884126.
6. Taşkömür AT, Erten Ö. The role of cystatin C, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the evaluation of kidney function in women with preeclampsia. Taiwan J Obstet Gynecol 2021;60:615-20. https://doi.org/10.1016/j.tjog.2021.05.007.
7. Gao Y, Guo Y, Hao W, Meng J, Miao Z, Hou A, et al. Correlation Analysis and Diagnostic Value of Serum Homocysteine, Cystatin C and Uric Acid Levels with the Severity of Coronary Artery Stenosis in Patients with Coronary Heart Disease. Int J Gen Med 2023;16:2719-31. https://doi.org/10.2147/IJGM.S411417.
8. Shaker A, Al-Saad R, Jasim R, Abdul-Amir H, Al-Hindy M, Makki H, et al. Biochemical Significance of Cystatin-C and High- Sensitive CRP in Patients with Acute Coronary Syndrome; any Clinical Correlation with Diagnosis and Ejection Fraction. Syst Rev 2020;11:301-8. https://doi.org/10.5530/srp.2020.3.35.
9. Tapper M, McGrowder DA, Dilworth L, Soyibo A. Cystatin C, Vitamin D and Thyroid Function Test Profile in Chronic Kidney Disease Patients. Diseases 2021;9:5. https://doi.org/10.3390/diseases9010005.
10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas. Rev Esp Cardiol 2021;74:790-9. https://doi.org/10.1016/j.recesp.2021.06.016.
11. Wang Y-S, Ye J, Yang X, Zhang G-P, Cao Y-H, Zhang R, et al. Association of retinol binding protein-4, cystatin C, homocysteine and high-sensitivity C-reactive protein levels in patients with newly diagnosed type 2 diabetes mellitus. Arch Med Sci AMS 2019;15:1203-16. https://doi.org/10.5114/aoms.2018.79565.
12. Xiong K, Zhang S, Zhong P, Zhu Z, Chen Y, Huang W, et al. Serum cystatin C for risk stratification of prediabetes and diabetes populations. Diabetes Metab Syndr Clin Res Rev 2023;17:102882. https://doi.org/10.1016/j.dsx.2023.102882.
13. Mader A, Saely C, Maechler M, Larcher B, Sprenger L, Plattner T, et al. Cystatin C predicts major cardiovascular events in patients with coronary artery disease both among patients with type 2 diabetes and in non-diabetic individuals. Atherosclerosis 2023;379:187-8. https://doi.org/10.1016/j.atherosclerosis.2023.06.623.
14. Yang X, Lin Q, Li X, Wu L, Xu W, Zhu Y, et al. Cystatin C Is an Important Biomarker for Cardiovascular Autonomic Dysfunction in Chinese Type 2 Diabetic Patients. J Diabetes Res 2019;2019:e1706964. https://doi.org/10.1155/2019/1706964.
15. Wang S, Liu Q, Guo F, Zhou X, Shi J, Xie Q. Clinical utility of serum cystatin C for prediction of multi-vessel disease by coronary angiography in type 2 diabetes mellitus patients with normal renal function. BMC Cardiovasc Disord 2020;20:183. https://doi.org/10.1186/s12872-020-01475-4.
16. Wei W, Li S, Liu J, Liu Y, Chen K, Chen S, et al. Prognostic value of creatinine-to-cystatin c ratio in patients with type 2 diabetes mellitus: a cohort study. Diabetol Metab Syndr 2022;14:176. https://doi.org/10.1186/s13098-022-00958-y.
17. Chen J, Yang Y, Dai C, Wang Y, Zeng R, Liu Q. Serum cystatin C is associated with the prognosis in acute myocardial infarction patients after coronary revascularization: a systematic review and meta-analysis. BMC Cardiovasc Disord 2022;22:156. https://doi.org/10.1186/s12872-022-02599-5.
18. Rothenbacher D, Rehm M, Iacoviello L, Costanzo S, Tunstall-Pedoe H, Belch JJF, et al. Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project. BMC Med 2020;18:300. https://doi.org/10.1186/s12916-020-01776-7.
19. Mansour AE, Abdelmoniem RO, Elbadawy AM, Ibrahim WM. The utility of estimation of glomerular filtration rate by serum cystatin C as a predictor of diabetic kidney disease in both type I and type II diabetic patients: a single center study. Egypt J Intern Med 2023;35:64. https://doi.org/10.1186/s43162-023-00243-y.
20. Yang F, Wang M, Chen Y, Wu J, Li Y. Association of cardio-renal biomarkers and mortality in the U.S.: a prospective cohort study. Cardiovasc Diabetol 2023;22:265. https://doi.org/10.1186/s12933-023-01986-2.
21. Ma C-C, Duan C-C, Huang R-C, Tang H-Q. Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis. Arch Med Sci 2020;16:648-56. https://doi.org/10.5114/aoms.2019.83511.
22. Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med 2017;5:161. https://doi.org/10.21037/atm.2017.03.107.
23. Grubb A. Cystatin C is Indispensable for Evaluation of Kidney Disease. EJIFCC 2017;28:268-76.
24. González KA, Stickel AM, Kaur SS, Ramos AR, González HM, Tarraf W. Serum Cystatin-C is linked to increased prevalence of diabetes and higher risk of mortality in diverse middle-aged and older adults. PLOS ONE 2022;17:e0270289. https://doi.org/10.1371/journal.pone.0270289.
25. Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, et al. Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMC Med 2021;19:66. https://doi.org/10.1186/s12916-021-01936-3.
26. Laucyte-Cibulskiene A, Sharma S, Christensson A, Nilsson PM. Early life factors in relation to albuminuria and estimated glomerular filtration rate based on cystatin C and creatinine in adults from a Swedish population-based cohort study. J Nephrol 2022;35:889-900. https://doi.org/10.1007/s40620-021-01159-y.
27. Guilherme A, Henriques F, Bedard AH, Czech MP. Molecular pathways linking adipose innervation to insulin action in obesity and diabetes mellitus. Nat Rev Endocrinol 2019;15:207-25. https://doi.org/10.1038/s41574-019-0165-y.
28. Huang Z, Zhong J, Zhang S, Xiong Z, Huang Y, Liu M, et al. Association between serum cystatin C and early impairment of cardiac function and structure in type 2 diabetes patients with normal renal function. Clin Cardiol 2022;45:1287-96. https://doi.org/10.1002/clc.23920.
29. Shen Y, Zhang X, Li C, Wang X, Ye Y, Yuan J, et al. Pressure overload promotes cystatin C secretion of cardiomyocytes to regulate the MAPK signaling pathway and mediate cardiac hypertrophy. Ann Transl Med 2020;8:1514. https://doi.org/10.21037/atm-20-7041.
Published
Issue
Section
License
Copyright (c) 2024 Maritza Anabel Tisalema-Panimboza, Edison Arturo Galárraga-Pérez (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.